176 related articles for article (PubMed ID: 27090900)
1. Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.
Qin G; Li X; Chen Z; Liao G; Su Y; Chen Y; Zhang W
Mol Neurobiol; 2017 Jul; 54(5):3264-3270. PubMed ID: 27090900
[TBL] [Abstract][Full Text] [Related]
2. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients.
Wan G; Xiang L; Sun X; Wang X; Li H; Ge W; Cao F
Oncotarget; 2017 Jan; 8(3):5382-5391. PubMed ID: 28036271
[TBL] [Abstract][Full Text] [Related]
3. High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma.
Zhang W; Chen H; Lv S; Yang H
Mol Neurobiol; 2016 May; 53(4):2354-60. PubMed ID: 25983032
[TBL] [Abstract][Full Text] [Related]
4. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
Pelloski CE; Mahajan A; Maor M; Chang EL; Woo S; Gilbert M; Colman H; Yang H; Ledoux A; Blair H; Passe S; Jenkins RB; Aldape KD
Clin Cancer Res; 2005 May; 11(9):3326-34. PubMed ID: 15867231
[TBL] [Abstract][Full Text] [Related]
5. TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells.
Pinet S; Bessette B; Vedrenne N; Lacroix A; Richard L; Jauberteau MO; Battu S; Lalloué F
Oncotarget; 2016 Aug; 7(31):50349-50364. PubMed ID: 27385098
[TBL] [Abstract][Full Text] [Related]
6. Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas.
Huang T; Li S; Yang Z; Liu J; Han Y
Mol Neurobiol; 2016 Nov; 53(9):6407-6412. PubMed ID: 26582467
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies.
Bian B; Li L; Yang J; Liu Y; Xie G; Zheng Y; Zeng L; Zeng J; Shen L
Cancer Cell Int; 2019; 19():259. PubMed ID: 31624472
[TBL] [Abstract][Full Text] [Related]
8. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
9. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C
Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979
[TBL] [Abstract][Full Text] [Related]
10. Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis.
Tong X; Ma Y; Liu T; Li Z; Liu S; Wu G; Fan H
Medicine (Baltimore); 2021 Apr; 100(17):e25631. PubMed ID: 33907118
[TBL] [Abstract][Full Text] [Related]
11. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review.
Tong X; Wang D; Liu S; Ma Y; Li Z; Tian P; Fan H
Int J Chron Obstruct Pulmon Dis; 2018; 13():409-418. PubMed ID: 29430175
[TBL] [Abstract][Full Text] [Related]
12. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts.
Kornblit B; Hellemann D; Munthe-Fog L; Bonde J; Strøm JJ; Madsen HO; Johansen JS; Garred P
Immunobiology; 2013 Oct; 218(10):1227-34. PubMed ID: 23706599
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis.
Wang J; Qi S; Zhu YB; Ding L
World J Clin Cases; 2022 Mar; 10(7):2184-2193. PubMed ID: 35321165
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal/proangiogenic factor YKL-40 related to glioblastomas and its relationship with the subventricular zone.
Batista KMP; Eulate-Beramendi SA; Pińa KYÁR; Figueira PR; Canal AF; Chasin JMA; Meilan Á; Ugalde R; Vega IF
Folia Neuropathol; 2017; 55(1):14-22. PubMed ID: 28430288
[No Abstract] [Full Text] [Related]
15. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
[TBL] [Abstract][Full Text] [Related]
16. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.
Pelloski CE; Lin E; Zhang L; Yung WK; Colman H; Liu JL; Woo SY; Heimberger AB; Suki D; Prados M; Chang S; Barker FG; Fuller GN; Aldape KD
Clin Cancer Res; 2006 Jul; 12(13):3935-41. PubMed ID: 16818690
[TBL] [Abstract][Full Text] [Related]
17. Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature.
Anghileri E; Castiglione M; Nunziata R; Boffano C; Nazzi V; Acerbi F; Finocchiaro G; Eoli M
Neurosurg Rev; 2016 Jan; 39(1):37-45; discussion 45-6. PubMed ID: 26212701
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Olig2 and YKL-40 expression: a clinicopathological/immunohistochemical study for the distinction between subventricular zone II and III glioblastomas.
Batista K; Costa B; Pablo I; Vega IF; Morales J; Alvarez AV; Meilán A; Astudillo A; Alvarez KY
Folia Neuropathol; 2016; 54(1):31-9. PubMed ID: 27179219
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
20. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
Nutt CL; Betensky RA; Brower MA; Batchelor TT; Louis DN; Stemmer-Rachamimov AO
Clin Cancer Res; 2005 Mar; 11(6):2258-64. PubMed ID: 15788675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
